Wounds and Injuries
Conditions
Keywords
Surgical incision, surgical complication, NPWT, negative pressure, colorectal surgery, dehisced
Brief summary
Surgical Site Complications (SSC's) are responsible for increased morbidity in patients undergoing surgery resulting in prolonged length of stay in the hospital while increasing treatment and hospital costs dramatically. Negative Pressure Wound Therapy (NPWT) use on closed incisions has been reported in the literature to reduce SSC's including Surgical Site Infections (SSI's), with many promising studies in general surgery, including some studies using single use NPWT. However, to date, there are very few randomised controlled trials (RCT's) using this intervention. When using PICOTM (NPWT) for this indication, patients may be discharged from hospital earlier, with the negative pressure incision management in place. This has implications in terms of cost savings for the health care system and enables the patient to be able to return to their normal daily routine more quickly. The hypothesis of this study is that PICO NPWT will reduce frequency of SSC's, in a 30 day follow up period, as compared to standard care in patients undergoing colorectal procedures.
Interventions
DEVICEPICO Softport V1.6
PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
OTHERStandard Care
Care path normally used by the hospital
Sponsors
Smith & Nephew, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The subject or legal guardian must provide written informed consent (reference section 9.1). 2. Subjects eighteen (18) years of age or older. 3. Willing and able to make all required study visits. 4. Able to follow instructions. 5. Males or females. 6. Subject must be classified as a high risk patient in terms of likelihood for SSC's (i.e., heavy smoker (more than 20 cigarettes per day), diabetic, BMI ≥ 30, immunocompromised) or be treated as an emergency patient with obstructed bowel, perforated bowel or peritonitis and be undergoing any of the following procedures:- Left hemicolectomy, right hemicolectomy, extended right hemicolectomy, sigmoidectomy, anterior rectum resection, total colectomy.
Exclusion criteria
1. Contraindications or hypersensitivity to the use of the investigational product or its components (e.g., silicone adhesives and polyurethane films \[direct contact with incision\], acrylic adhesives \[direct contact with skin\], polyethylene fabrics and super-absorbent powders \[polyacrylates\]) within the dressing. 2. Subjects with extremely fragile skin who require the use of SECURA non-sting barrier skin wipes and have hypersensitivity to the ingredients in the wipes. 3. Participation in another clinical trial (with use of investigational medicinal product or medical device) within thirty (30) days of Visit 1 or during the study. 4. Subjects with skin features (e.g., tattoos, pre-existing scarring) which, in the opinion of the Investigator, could interfere with the study assessments. 5. Subjects who have participated previously in this clinical trial. 6. Subjects with a reference incision (that is the largest incision that is made during the surgery and the one that is allocated to study treatment) less than 8cm. 7. Subjects with incisions exceeding 40 cm in length. 8. Subjects with incisions that are actively bleeding unless homeostasis has been achieved (to be confirmed during surgery). 9. Patients attending for a re-operation within the last 3 months. 10. Patients undergoing a procedure as part of palliative care (to be confirmed during surgery). 11. Patients with a systemic infection (that is not related to perforated bowel or peritonitis) at the time of surgery. 12. Patients with a known history of poor compliance with medical treatment. 13. Patients who also have a gynaecological procedure carried out during the colorectal procedure. 14. Patients other than those with a disease known to affect the immune system that are on steroids or other immune modulators known to impact healing. 15. Patients with a genetic or acquired healing defect. 16. Exposure of blood vessels, organs, bone or tendon within the incision (to be confirmed during surgery). 17. Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of complications in each group | 30 days |
Secondary
| Measure | Time frame |
|---|---|
| Haematoma incidence during a 30-day follow-up period | 30 days |
| Seroma incidence during a 30-day follow-up | 30 days |
| Time to surgical incision closure | 30 days |
| Total length of hospital stay, including readmissions during a 30-day follow-up period | 30 days |
| Dehiscence incidence during a 30-day follow-up period | 30 days |
| Total number of readmissions during a 30-day follow-up period | 30 days |
| To compare PICO against Standard Care for differences in Health Related Quality of Life (HRQoL) using SF-12 over the 14-day and 30-day follow-up period | 30 days |
| Overall per subject treatment cost for PICO and Standard Care | 30 days |
| Cost per Quality Adjusted Life Year (QALY) within a 30-day follow-up period | 30 days |
| Time to initial discharge during a 30-day follow-up period | 30 days |
Outcome results
None listed